Aldoss, I., Shultz, C., Hunter, B., Swoboda, D., Montesinos, P., Assouline, S., Fleming, S., Grove, C., Schuh, A., Taussig, D., Malloy, K., Cobbina, E., Zhang, J., Ayash-Rashkovsky, M., Clement, J., Stein, E., DiPersio, J. (2025). Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708. Blood. https://doi.org/10.1182/blood-2025-3425